Our multidisciplinary research group aims to shape the future of bone biopsies by establishing the workflow as well as the analytical technologies needed to perform spatial transcriptomics, spatial proteomics, and spatial metabolomics on cryosections of undecalcified bone.
Spatial omics technologies have the power to revolutionize research and diagnostic procedures in osteology. To expand the armamentarium available to bone research and osteological diagnostics we aim to link spatial omics technologies to established diagnostic procedures such as histomorphometry and bone material science. We believe that this holistic systems osteology approach will provide molecular insight into bone biology and disease mechanisms, will lead to a new level of diagnostic information, will form the basis of better treatment decisions, and will pave the way for novel therapies in the future.
Our current research aims to further explore the nature of the biochemical signals and the pathways involved in the molecular regulation of bone remodeling, and to improve our understanding of the regulation of secretion of the bone-derived hormone fibroblast growth factor-23 (FGF23) and of the pathophysiological sequelae of FGF23 excess.
